Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024

Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE), a leader in women's health innovation, has announced its upcoming second quarter 2024 financial results conference call and webcast. The event is scheduled for August 12, 2024, at 4:30 p.m. Eastern Time. The company will release its financial results for the quarter ended June 30, 2024, after market close on the same day. Investors can access the call via phone or live webcast, with dial-in numbers provided for both U.S. and international participants. The conference ID is 6756565. The webcast will be available under the Investors section of Daré's website and will remain accessible for replay until August 26, 2024.

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, August 12, 2024, to review its financial results for the quarter ended June 30, 2024 and to provide a company update. The company will release its financial results after the close of market on Monday, August 12, 2024, and prior to the conference call and webcast.

To access the conference call via phone, dial (646) 307-1952 (U.S.) or (888) 672-2415 (international). The conference ID number for the call is 6756565. The live webcast can be accessed under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. The webcast will be archived under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com and available for replay until August 26, 2024.

About Daré Bioscience
Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility.

The first FDA-approved product to emerge from Daré’s portfolio of women’s health product candidates is XACIATO™ (clindamycin phosphate) vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Organon commenced U.S. marketing of XACIATO in the fourth quarter of 2023. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil, the active ingredient in Viagra®, to treat female sexual arousal disorder (FSAD); and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about XACIATO, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré Bioscience leadership has been named on the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma 2022. In 2023, Daré's CEO was honored as one of Fierce Pharma’s Most Influential People in Biopharma for Daré’s contributions to innovation and advocacy in the women’s health space. Daré Bioscience placed #1 in the Small Company category of the San Diego Business Journal’s 2023 Best Places to Work Awards.

Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

Contacts:

Media and Investors on behalf of Daré Bioscience, Inc:

Camilla White / Simona Kormanikova
Dentons Global Advisors
DareBioscience@dentonsglobaladvisors.com / 1.212.466.6450

Source: Daré Bioscience, Inc.

FAQ

When will Daré Bioscience (DARE) release its Q2 2024 financial results?

Daré Bioscience will release its Q2 2024 financial results after market close on Monday, August 12, 2024.

What time is Daré Bioscience's (DARE) Q2 2024 earnings call scheduled for?

Daré Bioscience's Q2 2024 earnings call is scheduled for 4:30 p.m. Eastern Time on Monday, August 12, 2024.

How can investors access Daré Bioscience's (DARE) Q2 2024 earnings call?

Investors can access the call via phone by dialing (646) 307-1952 (U.S.) or (888) 672-2415 (international), or through a live webcast available on the company's investor relations website.

What is the conference ID for Daré Bioscience's (DARE) Q2 2024 earnings call?

The conference ID for Daré Bioscience's Q2 2024 earnings call is 6756565.

Until when will the replay of Daré Bioscience's (DARE) Q2 2024 earnings call be available?

The webcast replay of Daré Bioscience's Q2 2024 earnings call will be available until August 26, 2024.